Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 461

1.

Heparanase accelerates obesity-associated breast cancer progression.

Hermano E, Goldberg R, Rubinstein AM, Sonnenblick A, Maly B, Nahmias D, Li JP, Bakker MAH, van der Vlag J, Vlodavsky I, Peretz T, Elkin M.

Cancer Res. 2019 Sep 3. pii: canres.4058.2019. doi: 10.1158/0008-5472.CAN-18-4058. [Epub ahead of print]

PMID:
31481501
2.

Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds.

Mohan CD, Hari S, Preetham HD, Rangappa S, Barash U, Ilan N, Nayak SC, Gupta VK, Basappa, Vlodavsky I, Rangappa KS.

iScience. 2019 May 31;15:360-390. doi: 10.1016/j.isci.2019.04.034. Epub 2019 May 3. Review.

3.

Heparanase promotes glioma progression via enhancing CD24 expression.

Barash U, Spyrou A, Liu P, Vlodavsky E, Zhu C, Luo J, Su D, Ilan N, Forsberg-Nilsson K, Vlodavsky I, Yang X.

Int J Cancer. 2019 Sep 15;145(6):1596-1608. doi: 10.1002/ijc.32375. Epub 2019 May 14.

PMID:
31032901
4.

Heparanase protects the heart against chemical or ischemia/reperfusion injury.

Wang F, Pulinilkunnil T, Flibotte S, Nislow C, Vlodavsky I, Hussein B, Rodrigues B.

J Mol Cell Cardiol. 2019 Jun;131:29-40. doi: 10.1016/j.yjmcc.2019.04.008. Epub 2019 Apr 17.

PMID:
31004678
5.

Systemic LPS-induced Aβ-solubilization and clearance in AβPP-transgenic mice is diminished by heparanase overexpression.

Jendresen C, Digre A, Cui H, Zhang X, Vlodavsky I, Li JP, Nilsson LNG.

Sci Rep. 2019 Mar 14;9(1):4600. doi: 10.1038/s41598-019-40999-4.

6.

Heparanase inhibitors restrain mesothelioma.

Lapidot M, Barash U, Vlodavsky I, Pass H.

Oncotarget. 2018 Dec 7;9(96):36830-36832. doi: 10.18632/oncotarget.26243. eCollection 2018 Dec 7.

7.

Is host heparanase required for the rapid spread of heparan sulfate binding viruses?

Khanna M, Ranasinghe C, Browne AM, Li JP, Vlodavsky I, Parish CR.

Virology. 2019 Mar;529:1-6. doi: 10.1016/j.virol.2019.01.001. Epub 2019 Jan 3.

PMID:
30622027
8.

Specific Inhibition of Heparanase by a Glycopolymer with Well-Defined Sulfation Pattern Prevents Breast Cancer Metastasis in Mice.

Loka RS, Sletten ET, Barash U, Vlodavsky I, Nguyen HM.

ACS Appl Mater Interfaces. 2019 Jan 9;11(1):244-254. doi: 10.1021/acsami.8b17625. Epub 2018 Dec 31.

9.

Dendrimer Heparan Sulfate Glycomimetics: Potent Heparanase Inhibitors for Anticancer Therapy.

Zubkova OV, Ahmed YA, Guimond SE, Noble SL, Miller JH, Alfred Smith RA, Nurcombe V, Tyler PC, Weissmann M, Vlodavsky I, Turnbull JE.

ACS Chem Biol. 2018 Dec 21;13(12):3236-3242. doi: 10.1021/acschembio.8b00909. Epub 2018 Nov 29.

PMID:
30480427
10.

Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?

Hoß SG, Grundmann M, Benkel T, Gockel L, Schwarz S, Kostenis E, Schlesinger M, Ilan N, Vlodavsky I, Bendas G.

Thromb Haemost. 2018 Oct;118(10):1803-1814. doi: 10.1055/s-0038-1669922. Epub 2018 Sep 20.

PMID:
30235481
11.

The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.

Weissmann M, Bhattacharya U, Feld S, Hammond E, Ilan N, Vlodavsky I.

Matrix Biol. 2019 Apr;77:58-72. doi: 10.1016/j.matbio.2018.08.005. Epub 2018 Aug 7.

PMID:
30096360
12.

Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies.

Ostrovsky O, Grushchenko-Polaq AH, Beider K, Mayorov M, Canaani J, Shimoni A, Vlodavsky I, Nagler A.

Oncogenesis. 2018 Jun 29;7(6):51. doi: 10.1038/s41389-018-0060-8.

13.

Heparanase is expressed in adult human osteoarthritic cartilage and drives catabolic responses in primary chondrocytes.

Gibor G, Ilan N, Journo S, Sharabi A, Dreyer J, Gertel S, Singh P, Menachem A, Snir N, Elkayam O, Vlodavsky I, Arad U.

Osteoarthritis Cartilage. 2018 Aug;26(8):1110-1117. doi: 10.1016/j.joca.2018.05.013. Epub 2018 May 24.

14.

Patient derived xenografts (PDX) predict an effective heparanase-based therapy for lung cancer.

Katz A, Barash U, Boyango I, Feld S, Zohar Y, Hammond E, Ilan N, Kremer R, Vlodavsky I.

Oncotarget. 2018 Apr 10;9(27):19294-19306. doi: 10.18632/oncotarget.25022. eCollection 2018 Apr 10.

15.

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.

Barash U, Lapidot M, Zohar Y, Loomis C, Moreira A, Feld S, Goparaju C, Yang H, Hammond E, Zhang G, Li JP, Ilan N, Nagler A, Pass HI, Vlodavsky I.

J Natl Cancer Inst. 2018 Oct 1;110(10):1102-1114. doi: 10.1093/jnci/djy032.

16.

Overexpression of heparanase in mice promoted megakaryopoiesis.

Tan YX, Cui H, Wan LM, Gong F, Zhang X, Vlodavsky I, Li JP.

Glycobiology. 2018 May 1;28(5):269-275. doi: 10.1093/glycob/cwy011.

PMID:
29471321
17.

Prognostic significance of heparanase expression in primary and metastatic breast carcinoma.

Vornicova O, Naroditsky I, Boyango I, Shachar SS, Mashiach T, Ilan N, Vlodavsky I, Bar-Sela G.

Oncotarget. 2017 Dec 21;9(5):6238-6244. doi: 10.18632/oncotarget.23560. eCollection 2018 Jan 19.

18.

Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.

Cassinelli G, Dal Bo L, Favini E, Cominetti D, Pozzi S, Tortoreto M, De Cesare M, Lecis D, Scanziani E, Minoli L, Naggi A, Vlodavsky I, Zaffaroni N, Lanzi C.

Cancer Lett. 2018 Feb 28;415:187-197. doi: 10.1016/j.canlet.2017.12.009. Epub 2017 Dec 7.

PMID:
29225052
19.

Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression.

Vlodavsky I, Gross-Cohen M, Weissmann M, Ilan N, Sanderson RD.

Trends Biochem Sci. 2018 Jan;43(1):18-31. doi: 10.1016/j.tibs.2017.10.007. Epub 2017 Nov 20. Review.

20.

Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodeling.

Sanderson RD, Bandari SK, Vlodavsky I.

Matrix Biol. 2019 Jan;75-76:160-169. doi: 10.1016/j.matbio.2017.10.007. Epub 2017 Oct 26. Review.

PMID:
29106944
21.

Dual effects of hyperglycemia on endothelial cells and cardiomyocytes to enhance coronary LPL activity.

Chiu AP, Bierende D, Lal N, Wang F, Wan A, Vlodavsky I, Hussein B, Rodrigues B.

Am J Physiol Heart Circ Physiol. 2018 Jan 1;314(1):H82-H94. doi: 10.1152/ajpheart.00372.2017. Epub 2017 Oct 6.

22.

Targeting heparanase to the mammary epithelium enhances mammary gland development and promotes tumor growth and metastasis.

Boyango I, Barash U, Fux L, Naroditsky I, Ilan N, Vlodavsky I.

Matrix Biol. 2018 Jan;65:91-103. doi: 10.1016/j.matbio.2017.08.005. Epub 2017 Sep 13.

PMID:
28916201
23.

Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.

Bandari SK, Purushothaman A, Ramani VC, Brinkley GJ, Chandrashekar DS, Varambally S, Mobley JA, Zhang Y, Brown EE, Vlodavsky I, Sanderson RD.

Matrix Biol. 2018 Jan;65:104-118. doi: 10.1016/j.matbio.2017.09.001. Epub 2017 Sep 6.

24.

Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth.

Spyrou A, Kundu S, Haseeb L, Yu D, Olofsson T, Dredge K, Hammond E, Barash U, Vlodavsky I, Forsberg-Nilsson K.

Mol Cancer Ther. 2017 Aug;16(8):1705-1716. doi: 10.1158/1535-7163.MCT-16-0900. Epub 2017 Jul 17.

25.

Overexpression of heparanase enhances T lymphocyte activities and intensifies the inflammatory response in a model of murine rheumatoid arthritis.

Digre A, Singh K, Åbrink M, Reijmers RM, Sandler S, Vlodavsky I, Li JP.

Sci Rep. 2017 Apr 12;7:46229. doi: 10.1038/srep46229.

26.

Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545.

Abassi Z, Hamoud S, Hassan A, Khamaysi I, Nativ O, Heyman SN, Muhammad RS, Ilan N, Singh P, Hammond E, Zaza G, Lupo A, Onisto M, Bellin G, Masola V, Vlodavsky I, Gambaro G.

Oncotarget. 2017 May 23;8(21):34191-34204. doi: 10.18632/oncotarget.16573.

27.

The Role of Heparanase in the Pathogenesis of Acute Pancreatitis: A Potential Therapeutic Target.

Khamaysi I, Singh P, Nasser S, Awad H, Chowers Y, Sabo E, Hammond E, Gralnek I, Minkov I, Noseda A, Ilan N, Vlodavsky I, Abassi Z.

Sci Rep. 2017 Apr 6;7(1):715. doi: 10.1038/s41598-017-00715-6.

28.

Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity.

Baburajeev CP, Mohan CD, Rangappa S, Mason DJ, Fuchs JE, Bender A, Barash U, Vlodavsky I, Basappa, Rangappa KS.

BMC Cancer. 2017 Mar 31;17(1):235. doi: 10.1186/s12885-017-3214-8.

29.

Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma.

Binder Gallimidi A, Nussbaum G, Hermano E, Weizman B, Meirovitz A, Vlodavsky I, Götte M, Elkin M.

PLoS One. 2017 Mar 28;12(3):e0174343. doi: 10.1371/journal.pone.0174343. eCollection 2017.

30.

Loss of VEGFB and its signaling in the diabetic heart is associated with increased cell death signaling.

Lal N, Chiu AP, Wang F, Zhang D, Jia J, Wan A, Vlodavsky I, Hussein B, Rodrigues B.

Am J Physiol Heart Circ Physiol. 2017 Jun 1;312(6):H1163-H1175. doi: 10.1152/ajpheart.00659.2016. Epub 2017 Mar 17.

31.

Overexpression of heparanase attenuated TGF-β-stimulated signaling in tumor cells.

Batool T, Fang J, Barash U, Moustakas A, Vlodavsky I, Li JP.

FEBS Open Bio. 2017 Feb 11;7(3):405-413. doi: 10.1002/2211-5463.12190. eCollection 2017 Mar.

32.

The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression.

Singh P, Blatt A, Feld S, Zohar Y, Saadi E, Barki-Harrington L, Hammond E, Ilan N, Vlodavsky I, Chowers Y, Half E.

Neoplasia. 2017 Mar;19(3):175-184. doi: 10.1016/j.neo.2016.12.001. Epub 2017 Jan 29.

33.

Heparanase Overexpression Induces Glucagon Resistance and Protects Animals From Chemically Induced Diabetes.

Zhang D, Wang F, Lal N, Chiu AP, Wan A, Jia J, Bierende D, Flibotte S, Sinha S, Asadi A, Hu X, Taghizadeh F, Pulinilkunnil T, Nislow C, Vlodavsky I, Johnson JD, Kieffer TJ, Hussein B, Rodrigues B.

Diabetes. 2017 Jan;66(1):45-57. doi: 10.2337/db16-0761. Epub 2016 Oct 7.

34.

High glucose facilitated endothelial heparanase transfer to the cardiomyocyte modifies its cell death signature.

Wang F, Jia J, Lal N, Zhang D, Chiu AP, Wan A, Vlodavsky I, Hussein B, Rodrigues B.

Cardiovasc Res. 2016 Dec;112(3):656-668.

35.

Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, Ilan N.

Drug Resist Updat. 2016 Nov;29:54-75. doi: 10.1016/j.drup.2016.10.001. Epub 2016 Oct 6. Review.

36.

Heparanase is required for activation and function of macrophages.

Gutter-Kapon L, Alishekevitz D, Shaked Y, Li JP, Aronheim A, Ilan N, Vlodavsky I.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7808-E7817. Epub 2016 Nov 14.

37.

Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3.

Alishekevitz D, Gingis-Velitski S, Kaidar-Person O, Gutter-Kapon L, Scherer SD, Raviv Z, Merquiol E, Ben-Nun Y, Miller V, Rachman-Tzemah C, Timaner M, Mumblat Y, Ilan N, Loven D, Hershkovitz D, Satchi-Fainaro R, Blum G, Sleeman JP, Vlodavsky I, Shaked Y.

Cell Rep. 2016 Oct 25;17(5):1344-1356. doi: 10.1016/j.celrep.2016.09.083.

38.

Heparanase expression upregulates platelet adhesion activity and thrombogenicity.

Cui H, Tan YX, Österholm C, Zhang X, Hedin U, Vlodavsky I, Li JP.

Oncotarget. 2016 Jun 28;7(26):39486-39496. doi: 10.18632/oncotarget.8960.

39.

Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I.

FEBS J. 2017 Jan;284(1):42-55. doi: 10.1111/febs.13932. Epub 2016 Nov 16. Review.

40.

Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.

Ramani VC, Vlodavsky I, Ng M, Zhang Y, Barbieri P, Noseda A, Sanderson RD.

Matrix Biol. 2016 Sep;55:22-34. doi: 10.1016/j.matbio.2016.03.006. Epub 2016 Mar 22.

41.

The prognostic significance of heparanase expression in metastatic melanoma.

Vornicova O, Boyango I, Feld S, Naroditsky I, Kazarin O, Zohar Y, Tiram Y, Ilan N, Ben-Izhak O, Vlodavsky I, Bar-Sela G.

Oncotarget. 2016 Nov 15;7(46):74678-74685. doi: 10.18632/oncotarget.12492.

42.

Heparanase Overexpression Reduces Hepcidin Expression, Affects Iron Homeostasis and Alters the Response to Inflammation.

Asperti M, Stuemler T, Poli M, Gryzik M, Lifshitz L, Meyron-Holtz EG, Vlodavsky I, Arosio P.

PLoS One. 2016 Oct 6;11(10):e0164183. doi: 10.1371/journal.pone.0164183. eCollection 2016.

43.

Heparanase Promotes Glioma Progression and Is Inversely Correlated with Patient Survival.

Kundu S, Xiong A, Spyrou A, Wicher G, Marinescu VD, Edqvist PD, Zhang L, Essand M, Dimberg A, Smits A, Ilan N, Vlodavsky I, Li JP, Forsberg-Nilsson K.

Mol Cancer Res. 2016 Dec;14(12):1243-1253. Epub 2016 Aug 26. Erratum in: Mol Cancer Res. 2018 Apr;16(4):740-741.

44.

Heparanase: A Potential New Factor Involved in the Renal Epithelial Mesenchymal Transition (EMT) Induced by Ischemia/Reperfusion (I/R) Injury.

Masola V, Zaza G, Gambaro G, Onisto M, Bellin G, Vischini G, Khamaysi I, Hassan A, Hamoud S, Nativ O, Heyman SN, Lupo A, Vlodavsky I, Abassi Z.

PLoS One. 2016 Jul 28;11(7):e0160074. doi: 10.1371/journal.pone.0160074. eCollection 2016. Erratum in: PLoS One. 2017 Apr 10;12 (4):e0175618.

45.

Heparanase and cancer progression: New directions, new promises.

Arvatz G, Weissmann M, Ilan N, Vlodavsky I.

Hum Vaccin Immunother. 2016 Sep;12(9):2253-6. doi: 10.1080/21645515.2016.1171442. Epub 2016 Apr 7.

46.

Heparanase 2 Attenuates Head and Neck Tumor Vascularity and Growth.

Gross-Cohen M, Feld S, Doweck I, Neufeld G, Hasson P, Arvatz G, Barash U, Naroditsky I, Ilan N, Vlodavsky I.

Cancer Res. 2016 May 1;76(9):2791-801. doi: 10.1158/0008-5472.CAN-15-1975. Epub 2016 Mar 24.

47.

Heparanase 2 expression inversely correlates with bladder carcinoma grade and stage.

Gross-Cohen M, Feld S, Naroditsky I, Nativ O, Ilan N, Vlodavsky I.

Oncotarget. 2016 Apr 19;7(16):22556-65. doi: 10.18632/oncotarget.8003.

48.

Heparanase Is Essential for the Development of Acute Experimental Glomerulonephritis.

Garsen M, Benner M, Dijkman HB, van Kuppevelt TH, Li JP, Rabelink TJ, Vlodavsky I, Berden JH, Rops AL, Elkin M, van der Vlag J.

Am J Pathol. 2016 Apr;186(4):805-15. doi: 10.1016/j.ajpath.2015.12.008. Epub 2016 Feb 9.

PMID:
26873445
49.

Lung ICAM-1 and ICAM-2 support spontaneous intravascular effector lymphocyte entrapment but are not required for neutrophil entrapment or emigration inside endotoxin-inflamed lungs.

Petrovich E, Feigelson SW, Stoler-Barak L, Hatzav M, Solomon A, Bar-Shai A, Ilan N, Li JP, Engelhardt B, Vlodavsky I, Alon R.

FASEB J. 2016 May;30(5):1767-78. doi: 10.1096/fj.201500046. Epub 2016 Jan 28.

PMID:
26823454
50.

Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis.

Weissmann M, Arvatz G, Horowitz N, Feld S, Naroditsky I, Zhang Y, Ng M, Hammond E, Nevo E, Vlodavsky I, Ilan N.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):704-9. doi: 10.1073/pnas.1519453113. Epub 2016 Jan 4.

Supplemental Content

Loading ...
Support Center